title: Alterations by clofibric acid of glycerolipid metabolism in rat-kidney.
abstract: Alterations induced by p-chlorophenoxyisobutyric acid (clofibric acid) in glycerolipid metabolism in rat-kidney were studied. (1) The treatment of rats with clofibric acid markedly decreased renal level of triacylglycerol, which seemed to be due to a reduced formation of triacylglycerol, since the in vivo incorporation of [14C]oleic acid (18:1), [14C]linoleic acid (18:2) and [3H]glycerol into triacylglycerol was decreased in clofibric acid-fed rats. (2) The administration of clofibric acid to rats increased proportions of 18:1 and 18:2 and decreased a proportion of arachidonic acid (20:4) in phosphatidylcholine; the contents of two major molecular species of renal diacylglycerophosphocholine (diacyl-GPC), palmitoyl-arachidonoyl (16:0-20:4) and stearoylarachidonoyl (18:0-20:4), were both decreased markedly. The treatment did not alter renal content of phosphatidylcholine. (3) By contrast, clofibric acid changed, to a lesser extent, the composition of molecular species of diacylphosphatidylethanolamine. (4) The decrease in the level of diacyl-GPC that contains 20:4 seemed to be due to the clofibric acid-caused reduction in the concentration of free 20:4 in kidney. The reduction in renal concentration of free 20:4 seemed to be caused by a decrease in serum concentration of lipids that contain 20:4, but not by a decrease in the activities of desaturation and chain elongation that participate in biosynthesis of 20:4. (5) The reduction by clofibric acid in the renal content of diacyl-GPC containing 20:4 resulted in the decrease in the formation of prostaglandin E2 in kidney.
authors.affiliation: Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kawashima
authors.forename: K
authors.initials: K
authors.lastname: Musoh
authors.forename: H
authors.initials: H
authors.lastname: Kozuka
mesh_terms: D000818:Animals; D002250:Carbon Radioisotopes; D002995:Clofibric Acid / Q000494:pharmacology*; D015232:Dinoprostone / Q000096:biosynthesis; D005227:Fatty Acids / Q000032:analysis; D005989:Glycerides / Q000096:biosynthesis*; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D010713:Phosphatidylcholines / Q000096:biosynthesis*; D010714:Phosphatidylethanolamines / Q000096:biosynthesis; D010716:Phosphatidylinositols / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar
chemical_list: D002250:Carbon Radioisotopes; D005227:Fatty Acids; D005989:Glycerides; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010716:Phosphatidylinositols; D002995:Clofibric Acid; D015232:Dinoprostone